Patents Assigned to ZIOPHARM Oncology, Inc.
-
Patent number: 9346836Abstract: The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyper-proliferative disorders, also are disclosed.Type: GrantFiled: July 10, 2014Date of Patent: May 24, 2016Assignee: ZIOPHARM Oncology, Inc.Inventor: Lee R. Morgan
-
Patent number: 9340563Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.Type: GrantFiled: November 6, 2013Date of Patent: May 17, 2016Assignee: ZIOPHARM Oncology, Inc.Inventors: John C. Amedio, Jr., Barbara Wallner, Philip B. Komarnitsky
-
Patent number: 9254298Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A+ is an ammonium cation.Type: GrantFiled: July 23, 2015Date of Patent: February 9, 2016Assignee: ZIOPHARM Oncology, Inc.Inventors: Frank W. Waligora, John C. Amedio, Jr.
-
Patent number: 9145431Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A+ is an ammonium cation.Type: GrantFiled: January 29, 2014Date of Patent: September 29, 2015Assignee: ZIOPHARM Oncology, Inc.Inventors: Frank W. Waligora, John C. Amedio, Jr.
-
Publication number: 20140378704Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A+ is an ammonium cation.Type: ApplicationFiled: January 29, 2014Publication date: December 25, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Frank W. WALIGORA, John C. AMEDIO, JR.
-
Patent number: 8796329Abstract: Organic arsenical compounds are useful to inhibit angiogenesis in a variety of disease conditions.Type: GrantFiled: September 28, 2007Date of Patent: August 5, 2014Assignee: Ziopharm Oncology, Inc.Inventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20140212495Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.Type: ApplicationFiled: August 15, 2013Publication date: July 31, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Pavlos Papadopoulos, Gerhard Raab, Mark J. Doty, James E. Kipp, Berthold Roessler
-
Publication number: 20140194377Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.Type: ApplicationFiled: November 6, 2013Publication date: July 10, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: John C. AMEDIO, JR., Barbara WALLNER, Philip B. KOMARNITSKY
-
Publication number: 20140193519Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: August 2, 2013Publication date: July 10, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Barbara P. Wallner, Brian Eric Schwartz, Philip B. Komarnitsky, Gerald Bacher, Bernhard Kutscher, Gerhard Raab
-
Patent number: 8664201Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups and A+ is an ammonium cation.Type: GrantFiled: July 30, 2009Date of Patent: March 4, 2014Assignee: Ziopharm Oncology, Inc.Inventors: Frank Walter Waligora, John C. Amedio
-
Patent number: 8604007Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.Type: GrantFiled: April 4, 2008Date of Patent: December 10, 2013Assignee: Ziopharm Oncology, Inc.Inventors: John C. Amedio, Jr., Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20130261082Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent.Type: ApplicationFiled: March 6, 2013Publication date: October 3, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Barbara WALLNER, Philip B. KOMARNITSKY
-
Publication number: 20130196000Abstract: In one aspect, a method for treating a subject having a hyperproliferative disorder is disclosed, including administering to the subject a composition including: IPM, an IPM analog, or a pharmaceutically acceptable salt thereof in the dosage from about 70 mg/m2/day to about 160 mg/m2/day; etoposide in the dosage up to about 100 mg/m2/day; and one or more of carboplatin, cisplatin, oxaliplatin, picoplatin, or a combination thereof in the dosage of from AUC 2 mg/mL/min to AUC 7 mg/mL/min; wherein the treatment does not result in a dose limiting toxicity.Type: ApplicationFiled: January 30, 2013Publication date: August 1, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventor: Ziopharm Oncology, Inc.
-
Publication number: 20130142730Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: November 14, 2012Publication date: June 6, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventor: ZIOPHARM Oncology, Inc.
-
Publication number: 20130084345Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: November 20, 2012Publication date: April 4, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventor: Ziopharm Oncology, Inc.
-
Patent number: 8334398Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: GrantFiled: June 1, 2011Date of Patent: December 18, 2012Assignee: Ziopharm Oncology, Inc.Inventors: Paul Gutsch, Brian Renzelmann
-
Publication number: 20120295861Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent.Type: ApplicationFiled: July 26, 2012Publication date: November 22, 2012Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Barbara P. WALLNER, Philip B. KOMARNITSKY
-
Publication number: 20120219597Abstract: In certain embodiments, the invention relates to pharmaceutical formulations of an indolyl-3-glyoxylic acid derivative or a pharmaceutically acceptable salt thereof, such as indibulin. Methods of preparing such formulations and methods of treatment using these formulations are also described.Type: ApplicationFiled: September 1, 2010Publication date: August 30, 2012Applicant: ZIOPHARM Oncology, Inc.Inventor: John C. Amedio, JR.
-
Patent number: 8252773Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.Type: GrantFiled: October 31, 2008Date of Patent: August 28, 2012Assignee: Ziopharm Oncology, Inc.Inventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20120022229Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: June 1, 2011Publication date: January 26, 2012Applicant: Ziopharm Oncology, Inc.Inventors: Paul Gutsch, Brian Renzelmann